Andersson, Michael

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 2.

Journal Article

Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6

Francis, Prudence; Crown, John; Di Leo, Angelo; Buyse, Marc; Balil, Ana; Andersson, Michael; Nordenskjöld, Bo; Lang, Istvan; Jakesz, Raimund; Vorobiof, Daniel; Gutiérrez, Jorge; Van Hazel, Guy; Dolci, Stella; Jamin, Sophie; Bendahmane, Belguendouz; Gelber, Richard D.; Goldhirsch, Aron; Castiglione-Gertsch, Monica; Piccart-Gebhart, Martine (2008). Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial. Journal of the National Cancer Institute JNCI, 100(2), pp. 121-133. Oxford University Press 10.1093/jnci/djm287

This list was generated on Thu Dec 13 08:30:56 2018 CET.
Provide Feedback